Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
    Meeting Abstract

    Kelly, R. J.; Le, X.; Luttropp, K.; Yang, M.; Liu, F.; Huse, S.; Ganz, M. L.; Pfeiffer, B.; Paik, P. K.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
    Meeting Abstract

    De Langen, J.; Cho, B. C.; Piotrowska, Z.; Le, X.; Goldberg, S. B.; Goldman, J. W.; Okamoto, I.; Hewson, N.; Maidment, J.; Tang, K. H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, C.; Shim, B. Y.; Han, J. Y.; Drilon, A. E.; Lena, H.; Gomez, J. E.; Gray, J. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
    Meeting Abstract

    Drilon, A. E.; Chan, J.; Sands, J.; Tan, D. S. W.; Weiss, J.; Solomon, B.; Kim, Y. J.; Johnson, M. L.; Puri, T.; Sarno, M. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Smit, E. F.; Garassino, M. C.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Mazieres, J.; Cortot, A.; Raskin, J.; Thomas, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
    Meeting Abstract

    Ramalingam, S. S.; Zhou, C.; Kim, T. M.; Yang, J. C. H.; Riely, G. J.; Mekhail, T.; Nguyen, D.; Campelo, M. R. G.; Felip, E.; Misch, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Veluswamy, R.; Bhalla, S.; Samstein, R.; Marron, T.; Gomez, J. E.; Doroshow, D. B.; Sabari, J.; Shum, E.; Saxena, A.; Namakydoust, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluation of anxiety, distress and satisfaction with a multi-cancer early detection test
    Meeting Abstract

    Schrag, D.; Beer, T. M.; McDonnell, C. H.; Nadauld, L.; Dilaveri, C. A.; Klein, E. A.; Reid, R.; Marinac, C. R.; Chung, K. C.; Lopatin, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
    Meeting Abstract

    Smit, E. F.; Felip, E.; Uprety, D.; Nakagawa, K.; Paz-Ares, L.; Pacheco, J.; Li, B. T.; Planchard, D.; Baik, C.; Goto, Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
    Meeting Abstract

    Li, B. T.; Smit, E. F.; Goto, Y.; Nakagawa, K.; Goto, K.; Mazieres, J.; Uprety, D.; Bazhenova, L.; Saltos, A.; Felip, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save